These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 25955652

  • 1. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M, Corvo L, Garde E, Ramírez L, Iniesta V, Bonay P, Gómez-Nieto C, González VM, Martín ME, Alonso C, Coelho EA, Barral A, Barral-Netto M, Iborra S.
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
    [Abstract] [Full Text] [Related]

  • 2. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
    Iborra S, Abánades DR, Parody N, Carrión J, Risueño RM, Pineda MA, Bonay P, Alonso C, Soto M.
    Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
    [Abstract] [Full Text] [Related]

  • 3. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
    Ramirez L, Corvo L, Duarte MC, Chávez-Fumagalli MA, Valadares DG, Santos DM, de Oliveira CI, Escutia MR, Alonso C, Bonay P, Tavares CA, Coelho EA, Soto M.
    Parasit Vectors; 2014 Jan 02; 7():3. PubMed ID: 24382098
    [Abstract] [Full Text] [Related]

  • 4. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
    Pirdel L, Farajnia S.
    Scand J Immunol; 2017 Jul 02; 86(1):15-22. PubMed ID: 28426153
    [Abstract] [Full Text] [Related]

  • 5. Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.
    Fernández L, Carrillo E, Sánchez-Sampedro L, Sánchez C, Ibarra-Meneses AV, Jimenez MA, Almeida VDA, Esteban M, Moreno J.
    Front Immunol; 2018 Jul 02; 9():843. PubMed ID: 29740446
    [Abstract] [Full Text] [Related]

  • 6. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M.
    Infect Immun; 2005 Sep 29; 73(9):5842-52. PubMed ID: 16113303
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP.
    Microbes Infect; 2007 Jul 29; 9(9):1070-7. PubMed ID: 17644455
    [Abstract] [Full Text] [Related]

  • 9. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
    Elikaee S, Mohebali M, Rezaei S, Eslami H, Khamesipour A, Keshavarz H, Eshraghian MR.
    Vaccine; 2019 May 27; 37(24):3221-3228. PubMed ID: 31047672
    [Abstract] [Full Text] [Related]

  • 10. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N, Zahedifard F, Doroud D, Doustdari F, Vasei M, Papadopoulou B, Rafati S.
    Parasite Immunol; 2013 Dec 27; 35(12):397-408. PubMed ID: 23710803
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC, Régis WC, Costa LE, de Oliveira JS, da Silva AG, Martins VT, Duarte MC, de Souza JR, Lage PS, Schneider MS, Melo MN, Soto M, Soares SA, Tavares CA, Chávez-Fumagalli MA, Coelho EA.
    Exp Parasitol; 2015 Jun 27; 153():180-90. PubMed ID: 25845753
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection.
    Ribeiro PAF, Dias DS, Lage DP, Martins VT, Costa LE, Santos TTO, Ramos FF, Tavares GSV, Mendonça DVC, Ludolf F, Gomes DA, Rodrigues MA, Chávez-Fumagalli MA, Silva ES, Galdino AS, Duarte MC, Roatt BM, Menezes-Souza D, Teixeira AL, Coelho EAF.
    Mol Immunol; 2019 Feb 27; 106():108-118. PubMed ID: 30594673
    [Abstract] [Full Text] [Related]

  • 13. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA, Machado AS, Ramos FF, Tavares GSV, Lage DP, Mendonça DVC, Pereira IAG, Santos TTO, Martins VT, Carvalho LM, Freitas CS, Ludolf F, Reis TAR, Bandeira RS, Silva AM, Costa LE, Oliveira JS, Duarte MC, Roatt BM, Teixeira AL, Coelho EAF.
    Cell Immunol; 2020 Oct 27; 356():104194. PubMed ID: 32827943
    [Abstract] [Full Text] [Related]

  • 14. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.
    Vaccine; 2012 Feb 08; 30(7):1357-63. PubMed ID: 22210224
    [Abstract] [Full Text] [Related]

  • 15. Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis.
    Dias DS, Ribeiro PAF, Martins VT, Lage DP, Portela ÁSB, Costa LE, Salles BCS, Lima MP, Ramos FF, Santos TTO, Caligiorne RB, Chávez-Fumagalli MA, Silveira JAG, Magalhães-Soares DF, Gonçalves DU, Oliveira JS, Roatt BM, Duarte MC, Menezes-Souza D, Silva ES, Galdino AS, Machado-de-Ávila RA, Teixeira AL, Coelho EAF.
    Mol Immunol; 2017 Nov 08; 91():272-281. PubMed ID: 28988041
    [Abstract] [Full Text] [Related]

  • 16. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
    Ribeiro PAF, Dias DS, Lage DP, Costa LE, Martins VT, Tavares GSV, Mendonça DVC, Lima MP, Oliveira JS, Steiner BT, Machado-de-Ávila RA, Roatt BM, Chávez-Fumagalli MA, Menezes-Souza D, Duarte MC, Teixeira AL, Coelho EAF.
    Cell Immunol; 2018 Sep 28; 331():67-77. PubMed ID: 29871740
    [Abstract] [Full Text] [Related]

  • 18. Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis.
    Dias DS, Ribeiro PAF, Martins VT, Lage DP, Costa LE, Chávez-Fumagalli MA, Ramos FF, Santos TTO, Ludolf F, Oliveira JS, Mendes TAO, Silva ES, Galdino AS, Duarte MC, Roatt BM, Menezes-Souza D, Teixeira AL, Coelho EAF.
    Transl Res; 2018 Oct 28; 200():18-34. PubMed ID: 29908151
    [Abstract] [Full Text] [Related]

  • 19. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
    Costa LE, Goulart LR, Pereira NC, Lima MI, Duarte MC, Martins VT, Lage PS, Menezes-Souza D, Ribeiro TG, Melo MN, Fernandes AP, Soto M, Tavares CA, Chávez-Fumagalli MA, Coelho EA.
    PLoS One; 2014 Oct 28; 9(10):e110014. PubMed ID: 25333662
    [Abstract] [Full Text] [Related]

  • 20. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.
    Martins VT, Chávez-Fumagalli MA, Costa LE, Canavaci AM, Martins AM, Lage PS, Lage DP, Duarte MC, Valadares DG, Magalhães RD, Ribeiro TG, Nagem RA, Darocha WD, Régis WC, Soto M, Coelho EA, Fernandes AP, Tavares CA.
    PLoS Negl Trop Dis; 2013 Oct 28; 7(3):e2148. PubMed ID: 23573301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.